Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children

Thorax

Volumn 51, Issue 9, 1996, Pages 941-943

  Clark, D J ^a   Clark, R A ^a   Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adrenal suppression; Asthmatic children; Budesonide; Fluticasone propionate; Inhaled cordcosteroid

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; PLACEBO;

ADOLESCENT; ADRENAL SUPPRESSION; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE;

EID: 0029738377     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.51.9.941     Document Type: Article

References (15)

1. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995;50:105-10.
2. Melchor R, Biddiscombe MF, Mak VHF, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993;48:506-11.
3. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990;84(Suppl A): 25-9.
4. Ryrfeldt A, Anderson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1963; (Suppl 122): 86-95.
5. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994;149(Suppl):A212.
6. Phillips GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990;84(Suppl A):19-23.
7. Wurthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss 1992; 4:161-7.
8. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
9. Thorsson L, Dahlström K, Edsbacker S, Källen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled flucticasone propionate in healthy subjects. Br J Clin Pharmacol 1996 (in press).
10. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from turbohaler is twice that from a pressurised metered-dose inhaler (pMDI). Eur Respir J 1994; 7:1839-44.
11. Pedersen S, Steffensen G, Ekman I, Tonnesson M, Borga A. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987;31:579-82.
12. Clark DJ, Grove A, Cargill R, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51:262-6.
13. Wolthers OD, Pedersen S. Measures of systemic activity of inhaled corticosteroids in children: a comparison of urine cortisol excretion and knemometry. Respir Med 1995; 89:347-9.
14. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1984;129:723-4.
15. Lonnebo A, Grahnen A, Ling-Anderson A, Brundin RM, Eckernas SA. A comparison of the effects on the HPA axis of single and repeated doses of inhaled fluticasone propionate and budesonide. Am J Respir Crit Care Med 1995; 151(Suppl):A375.